Abstract
To investigate the function of microRNA-31 (miR-31) in the pathogenesis of gastric cancer (GC) and to explore the possible mechanisms involved in it. A quantitative real-time reverse transcription-PCR (RT-PCR) analysis was performed to evaluate miR-31 expression in GC cell lines. After transfecting GC cells with miR-31 precursors, Alamar blue and apoptosis assays were used to measure the respective proliferation and apoptosis rates. SGPP2 and Smad4 expression were determined by real-time RT-PCR and western blot assays after miR-31 transfection. Animal assay was used to further investigate miR-31 in the pathogenesis of GC. miR-31 was significantly reduced in GC tissues and GC cell lines, and that the reduced miR-31 was associated with distant metastasis and GC clinical pathological stages, miR-31 was lower at stages III/IV than that at stage II. SGPP2 and Smad4 were proven to be the direct target of miR-31. SGPP2 and Smad4 at mRNA and protein levels were negatively correlated with miR-31 in human GC tissues and cancer cell lines. Increased miR-31 significantly repressed SGPP2 and Smad4 at transcriptional and translational levels. Functional studies showed that increasing miR-31 inhibited GC cell proliferation, promoted apoptosis and attenuated cell migration, which were also linked to downregulation of STAT3. In vivo, miR-31 inhibited GC cell growth in tumor-bearing mice. This study has revealed miR-31 as a tumor suppressor and has identified SGPP2 and Smad4 as novel targets of miR-31, linking to STAT3 for regulating cancer cell proliferation, apoptosis and migration in GC. Therefore, miR-31 could be a useful biomarker for monitoring GC development and progression, and also could have a therapeutic potential by targeting SGPP2, Smad4 and STAT3 for GC therapy.
Similar content being viewed by others
Change history
05 April 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41417-021-00325-5
References
Luo HQ, Han L, Jiang Y . Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev 2014; 15: 5343–5348.
Lyu X, Huang J, Liu J, Wang W, Su Y, Zhang W et al. Detection and significance of epidermal growth factor receptor mutation in esophageal, esophagogastric junction and gastric cancers. Zhonghua Zhong Liu Za Zhi 2014; 36: 346–350.
Peng N, Zhao X . Comparison of K-ras mutations in lung, colorectal and gastric cancer. Oncol Lett 2014; 8: 561–565.
Liu G, Jiang C, Li D, Wang R, Wang W . MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol 2014; 35: 9801–9806.
Smyth EC, Sclafani F, Cunningham D . Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014; 7: 1001–1014.
Rolfo C, Bronte G, Sortino G, Papadimitriou K, Passiglia F, Fiorentino E et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol 2014; 8: 1–11.
Guan SS, Chang J, Cheng CC, Luo TY, Ho AS, Wang CC et al. Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. Oncotarget 2014; 5: 4868–4880.
Luo BH, **ong F, Wang JP, Li JH, Zhong M, Liu QL et al. Epidermal growth factor-like domain-containing protein 7 (EGFL7) enhances EGF receptor-AKT signaling, epithelial-mesenchymal transition, and metastasis of gastric cancer cells. PLoS One 2014; 9: e99922.
Vaiopoulos AG, Kostakis ID, Gkioka E, Athanasoula KCh, Pikoulis E, Papalambros A et al. Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res 2014; 34: 3083–3092.
Choi MR, An CH, Chung YJ, Choi YJ, Yoo NJ, Lee SH . Mutational and expressional analysis of ERBB3 gene in common solid cancers. APMIS 2014; 122: 1207–1212.
Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A et al. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J 2014; 28: 4055–4067.
Xu L, Qu X, Li H, Li C, Liu J, Zheng H et al. Src/caveolin-1-regulated EGFR activation antagonizes TRAIL-induced apoptosis ingastric cancer cells. Oncol Rep 2014; 32: 318–324.
Aprile G, Giampieri R, Bonotto M, Bittoni A, Ongaro E, Cardellino GG et al. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Invest Drugs 2014; 23: 925–942.
Kurokawa Y, Matsuura N, Kawabata R, Nishikawa K, Ebisui C, Yokoyama Y et al. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. Ann Surg Oncol 2014; 21 (Suppl 4): S584–S590.
Nielsen TO, Friis-Hansen L, Poulsen SS, Federspiel B, Sorensen BS . Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. PLoS One 2014; 9: e94606.
Wei J, Zhao ZX, Li Y, Zhou ZQ, You TG . Cortactin expression confers a more malignant phenotype to gastric cancer SGC-7901 cells. World J Gastroenterol 2014; 20: 3287–3300.
Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H . Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother 2014; 63: 581–586.
Yan M, Parker BA, Schwab R, Kurzrock R . HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 2014; 40: 770–780.
Naruke A, Azuma M, Takeuchi A, Ishido K, Katada C, Sasaki T et al. Comparison of site-specific gene expression levels in primary tumors and synchronous lymph node metastases in advanced gastric cancer. Gastric Cancer 2014; 18: 262–270.
Chaturvedi R, Asim M, Piazuelo MB, Yan F, Barry DP, Sierra JC et al. Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastricepithelial cells with DNA damage. Gastroenterology 2014; 146: 1739–51.e14.
Jiang L, Chen Y, Sang J, Li Y, Lan T, Wang Y, Type II et al. cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells. Biomed Rep 2013; 1: 399–404.
Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2014; 18: 227–238.
Zhang J, Cao J, Li J, Zhang Y, Chen Z, Peng W et al. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. J. Hematol Oncol 2014; 7: 22.
Ye B, Jiang LL, Xu HT, Zhou DW, Li ZS . Expression of PI3K/AKT pathway in gastric cancer and its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol 2012; 25: 627–636.
**e J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep 2014; 31: 1715–1722.
Jiang L, Chen Y, Li Y, Lan T, Wu M, Wang Y et al. Type II cGMP-dependent protein kinase inhibits ligand-induced activation of EGFR ingastric cancer cells. Mol Med Rep 2014; 9: 1405–1409.
Gala K, Chandarlapaty S . Molecular pathways: HER3 targeted therapy. Clin Cancer Res 2014; 20: 1410–1416.
Agaimy A, Rau TT, Hartmann A, Stoehr R . SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol 2014; 38: 910–920.
Tajiri R, Ooi A, Fujimura T, Dobashi Y, Oyama T, Nakamura R et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol 2014; 45: 725–734.
Zhang L, Zhao G, Hou Y, Zhang J, Hu J, Zhang K . The experimental study on the treatment of cytokine-induced killer cells combined with EGFR monoclonal antibody against gastric cancer. Cancer Biother Radiopharm 2014; 29: 99–107.
Terragni R, Casadei Gardini A, Sabattini S, Bettini G, Amadori D, Talamonti C et al. EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model? PLoS One 2014; 9: e85388.
Shi M, Shi H, Ji J, Cai Q, Chen X, Yu Y et al. Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status. Curr Cancer Drug Targets 2014; 14: 217–224.
Zhang J, Zhan Z, Wu J, Zhang C, Yang Y, Tong S et al. Relationship between EGF, TGFA, and EGFR gene polymorphisms and traditional Chinese medicine ZHENG in gastric cancer. Evid Based Complement Alternat Med 2013; 2013: 731071.
Feng D, Ma Y, Liu J, Xu L, Zhang Y, Qu J et al. Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells. Int J Mol Sci 2013; 14: 24399–24411.
Aydin K, Okutur SK, Bozkurt M, Turkmen I, Namal E, Pilanci K et al. Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: a pilot study. Oncol Lett 2014; 7: 255–259.
Ito A, Ito Y, Matsushima S, Tsuchida D, Ogasawara M, Hasegawa J et al. New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice. Gastric Cancer 2014; 17: 497–507.
Hong L, Han Y, Brain L . The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer. Expert Rev Gastroenterol Hepatol 2014; 8: 111–117.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
About this article
Cite this article
Ruoming, W., Zhen, Y., Tengteng, Z. et al. RETRACTED ARTICLE: Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2. Cancer Gene Ther 22, 564–572 (2015). https://doi.org/10.1038/cgt.2015.41
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2015.41
- Springer Nature America, Inc.
This article is cited by
-
Retraction Note: MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma
Cancer Gene Therapy (2021)
-
Unique microRNA alterations in hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice
Archives of Toxicology (2020)